Home  |  Important Safety Information  |  Full Prescribing Information PDF
Contact Us  |  Site Map
A
A
A
Print

Migraine Attacks Can Be Long in Duration, and Often Recur


      * In at least 2 out of 3 menstrual cycles.

Menstruation may increase the risk of occurrence of migraine by up to 96%18

This was a prospective study in which factors related to migraine attacks were analyzed using diary data from 327 adult migraineurs over 3 months. The hazard for occurrence and persistence of migraine was determined by univariate Cox regression analyses and 2 stepwise multivariate Cox regression analyses for those covariables that showed a P value of <0.05 in the univariate analyses.18

For more information, please see Full Prescribing Information for FROVA at http://www.frova.com/pi.

If you are a Vermont prescriber, additional information is available.

References
  1. Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006;46(6):942-953.
  2. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773-780.
  3. Headache Classification Subcommittee of the International Headache Society (IHS). The international classification of headache disorders. Cephalalgia. 2004;24(suppl 1):8-160.
  4. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1-12.
  5. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657.
  6. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate to severe. Curr Med Res Opin. 2004;20(9):1465-1472. doi:10.1185/030079904X2745.
  7. Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002;42(suppl 2):S84-S92.
  8. FROVA® [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc; 2007.
  9. Physicians' Desk Reference. 65th ed. Montvale, NJ: Physicians' Desk Reference Inc; 2011.
  10. RELPAX® [package insert]. New York, NY: Pfizer Inc; 2008.
  11. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33(7):385-389.
  12. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2001;42(3):185-193.
  13. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20(8):701-707.
  14. Couturier EG, Bomhof MA, Neven AK, van Dukin NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23(4):302-308.
  15. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24(9):707-716.
  16. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63(2):351-353.
  17. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(12):2154-2158.
  18. Wober C, Brannath W, Schmidt K, et al; for the PAMINA Study Group. Prospective analysis of factors related to migraine attacks: the PAMINA study. Cephalalgia. 2007;27(4):304-314.
  19. US Department of Health and Human Services, Office on Women's Health. Migraine. http://www.womenshealth.gov/faq/migraine.pdf. Accessed June 29, 2010.